Xinlitai (002294.SZ): Innovative small molecule drug SAL0140 tablets obtained clinical trial approval.

The Zhitong Finance and Economics APP learned that Xintai (002294.SZ) has announced that the company recently received a Clinical Trial Approval Notice issued by the National Medical Products Administration, approving the company to conduct clinical trials for the innovative small molecule drug SAL0140 tablet (project code: SAL0140) for the treatment of chronic kidney disease (CKD).